Compare ARLP & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARLP | ZLAB |
|---|---|---|
| Founded | 1971 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 1999 | 2017 |
| Metric | ARLP | ZLAB |
|---|---|---|
| Price | $25.22 | $26.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $32.33 | ★ $34.13 |
| AVG Volume (30 Days) | 311.8K | ★ 1.1M |
| Earning Date | 10-26-2026 | 11-05-2026 |
| Dividend Yield | ★ 9.57% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,002,857,000.00 | $460,156,000.00 |
| Revenue This Year | $2.94 | N/A |
| Revenue Next Year | $3.94 | $22.41 |
| P/E Ratio | $10.68 | ★ N/A |
| Revenue Growth | 11.50 | ★ 15.33 |
| 52 Week Low | $23.01 | $15.96 |
| 52 Week High | $29.45 | $29.02 |
| Indicator | ARLP | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 60.15 |
| Support Level | $23.96 | $24.24 |
| Resistance Level | $25.33 | $26.64 |
| Average True Range (ATR) | 0.59 | 1.30 |
| MACD | -0.15 | 0.50 |
| Stochastic Oscillator | 38.10 | 64.22 |
Alliance Resource Partners LP operates as a coal mining company based in the United States. It has four segments: Illinois Basin, Appalachia, Oil & Gas Royalties, and Coal Royalties. The Illinois Basin comprises underground mining complexes in Illinois, Indiana, Kentucky, Maryland, and West Virginia. The Appalachia segment comprises the Mettiki mining complex, the Tunnel Ridge mining complex, and the MC Mining complex. The Oil & Gas Royalties has oil & gas mineral interests held by AR Midland and AllDale I & II, and includes Alliance Minerals' equity interests in both AllDale III and Cavalier Minerals. The Coal Royalties have included coal mineral reserves and resources owned or leased by Alliance Resource Properties.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.